Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.

Nara, Hiroshi; Sato, Kenjiro; Kaieda, Akira; Oki, Hideyuki; Kuno, Haruhiko; Santou, Takashi; Kanzaki, Naoyuki; Terauchi, Jun; Uchikawa, Osamu; Kori, Masakuni

Nara, Hiroshi; Sato, Kenjiro; Kaieda, Akira; Oki, Hideyuki; Kuno, Haruhiko; Santou, Takashi; Kanzaki, Naoyuki; Terauchi, Jun; Uchikawa, Osamu; Kori, Masakuni.

Afiliación

Nara H; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Sato K; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Kaieda A; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Oki H; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Kuno H; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Santou T; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Kanzaki N; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Terauchi J; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Uchikawa O; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Kori M; Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.

Bioorg Med Chem ; 24(23): 6149-6165, 2016 12 01.

Article en En | MEDLINE | ID: mdl-27825552

Asunto(s)

Amidas/farmacología; Metaloproteinasa 13 de la Matriz/metabolismo; Inhibidores de la Metaloproteinasa de la Matriz/farmacología; Pirimidinas/farmacología; Quinazolinonas/farmacología; Triazoles/farmacología; Zinc/química; Proteína ADAM17/antagonistas & inhibidores; Amidas/síntesis química; Amidas/farmacocinética; Animales; Diseño de Fármacos; Humanos; Inhibidores de la Metaloproteinasa de la Matriz/síntesis química; Inhibidores de la Metaloproteinasa de la Matriz/farmacocinética; Microsomas Hepáticos/metabolismo; Pirimidinas/síntesis química; Pirimidinas/farmacocinética; Quinazolinonas/síntesis química; Quinazolinonas/farmacocinética; Ratas; Triazoles/síntesis química; Triazoles/farmacocinética

Palabras clave

Fused pyrimidine-2-carboxamide; MMP-13; Matrix metalloproteinase; Osteoarthritis; Structure-based drug design; Zinc-binding group

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Pirimidinas / Triazoles / Zinc / Quinazolinonas / Metaloproteinasa 13 de la Matriz / Inhibidores de la Metaloproteinasa de la Matriz / Amidas Tipo de estudio: Prognostic_studies Idioma: En Revista: Bioorg Med Chem Asunto de la revista: BIOQUIMICA / QUIMICA Año: 2016 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google